Streetbeat News

Analyst Ratings

SONY

Goldman Sachs analyst Minami Munakata has upgraded Sony Group (NYSE:SONY) from Neutral to Buy, and added it to the conviction buy list.

Portfolio Pulse from Benzinga Newsdesk

July 12, 2023 | 5:22 pm

MRNA

A large bearish position on Moderna (NASDAQ:MRNA) has been noticed, with 15 uncommon options trades spotted. The sentiment of these big-money traders is split between 46% bullish and 53% bearish. Whales have been targeting a price range from $100.0 to $165.0 for Moderna over the last 3 months. UBS upgraded its action to Buy with a price target of $191, while Morgan Stanley maintained their Equal-Weight rating with a price target of $128.

Portfolio Pulse from Benzinga Insights

July 12, 2023 | 5:19 pm

SIBN

Needham analyst David Saxon reiterated a Buy rating on SI-BONE, Inc (NASDAQ:SIBN), raising the price target to $32 from $27. The analyst expects SIBN to beat and raise in 2Q and sees further upside to 2H23 estimates. Factors such as sales force expansion, surgeon training, new product launches, and increased market penetration are expected to drive quarterly revenue growth. SIBN is predicted to end 2Q with >$150 million in cash and equivalents. The analyst also forecasts an upside on the bottom line throughout 2023.

Portfolio Pulse from Nabaparna Bhattacharya

July 12, 2023 | 5:18 pm

SONY

Goldman Sachs has upgraded Sony Group to a Buy rating.

Portfolio Pulse from Benzinga Newsdesk

July 12, 2023 | 5:14 pm

ATZAF

Canaccord Genuity analyst Derek Dley maintains a 'Buy' rating on Aritzia (OTC:ATZAF) but lowers the price target from $50 to $37.

Portfolio Pulse from Benzinga Newsdesk

July 12, 2023 | 5:12 pm

ATZAF

BMO Capital analyst Stephen MacLeod has maintained a 'Market Perform' rating on Aritzia (OTC:ATZAF) but lowered the price target from C$50 to C$37.

Portfolio Pulse from Benzinga Newsdesk

July 12, 2023 | 5:10 pm

RXRX

Needham has reiterated its buy rating for Recursion Pharmaceuticals, maintaining a price target of $17. The company's stock symbol is RXRX.

Portfolio Pulse from Benzinga Newsdesk

July 12, 2023 | 5:10 pm

CSCO

Bank of America Securities has downgraded Cisco Systems from Buy to Neutral, leading to a decrease in the company's stock price.

Portfolio Pulse from Benzinga Newsdesk

July 12, 2023 | 5:06 pm

ELV

Elevance Health's stock has been downgraded from Outperform to Peer Perform by Wolfe Research, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

July 12, 2023 | 5:04 pm

LOW

Lowe's Companies (NYSE:LOW) has received a mix of bullish and indifferent analyst ratings over the last quarter. The average price target from these 13 analysts is $232.62, slightly below the current price of $233.61, implying a potential downside. This average has decreased by 0.29% from the previous average price target of $233.30.

Portfolio Pulse from Benzinga Insights

July 12, 2023 | 5:02 pm